| Reference : Growth hormone and somatostatin gene expression in pituitary adenomas with active acrome... |
| Scientific journals : Article | |||
| Life sciences : Biochemistry, biophysics & molecular biology | |||
| http://hdl.handle.net/2268/20100 | |||
| Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation | |
| English | |
| Pagesy, Patrick [ > > ] | |
| Li, Jacques Y. [ > > ] | |
Rentier-Delrue, Françoise [Université de Liège - ULg > Département des sciences de la vie > Biologie et génétique moléculaire - GIGA-R : Coordination scientifique >] | |
| Delalande, Olivier [ > > ] | |
| Le Bouc, Yves [ > > ] | |
| Kujas, Michèle [ > > ] | |
| Bression, Dominique [ > > ] | |
Martial, Joseph [Université de Liège - ULg > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >] | |
| Peillon, Françoise [ > > ] | |
| 1990 | |
| Acta Endocrinologica | |
| Periodica | |
| 122 | |
| 6 | |
| 745-752 | |
| 0001-5598 | |
| Copenhagen | |
| Denmark | |
| [en] Growth hormone ; somatostatin ; pituitary adenomas | |
| [en] Some patients with active acromegaly have elevated plasma IGF-I concentrations with only minimal elevation of plasma GH. We compared adenomatous GH and SRIH expression in 3 such patients (patients No. 1, 2 and 3; basal plasma GH level < 4 µg/l) and in 3 acromegalic patients with high basal plasma GH level (patients No. 4, 5 and 6; 51.7 ± 16.1 µg/l, mean ± SEM). By immunocytochemistry, all the tumours proved to be somatotropic adenomas. At the ultrastructural level, signs of low secretory activity were observed in adenomas from patients No. 2 and 3. Perifused adenoma cells of patients No. 1, 2 and 3 released very little GH compared with those of patients No. 4, 5 and 6 (1± 0.37 vs 51.5± 34.1 µg · (10–6 cells) · min–1, p< 0.001). Adenoma SRIH content was 65.7 and 30.6 pg/mg proteins in patients No. 1 and 2, whereas it was undetectable in the others (patients No. 4, 5 and 6). Northern blot analysis showed that the GH gene was poorly expressed in the adenomas from patients No. 1, 2 and 3 compared with the adenomas from patients No. 4, 5 and 6. SRIH mRNA was detected in all 6 adenomas. However, the signal was more intense in the adenomas from patients No. 1, 2 and 3 than in those from patients No. 4, 5 and 6. In conclusion, because of the variability of the biosynthetic and secretory potential of the somatotropic adenomas, patients harbouring this type of pituitary tumours can exhibit a wide range of plasma GH levels. In acromegaly with minimal elevation of plasma GH, the synthesis of SRIH by the adenoma cells themselves could play a role in the inhibition of GH expression. | |
| http://hdl.handle.net/2268/20100 | |
| 10.1530/acta.0.1220745 | |
| http://eje-online.org/cgi/content/abstract/122/6/745 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.